JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$2.54B |
| 2 |
Amazon
AMZN
|
+$1.38B |
| 3 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$827M |
| 4 |
Public Service Enterprise Group
PEG
|
+$725M |
| 5 |
Union Pacific
UNP
|
+$721M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.49B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.03B |
| 3 |
McDonald's
MCD
|
+$1.01B |
| 4 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$871M |
| 5 |
Exelon
EXC
|
+$709M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.19% |
| 2 | Technology | 14.28% |
| 3 | Healthcare | 12.84% |
| 4 | Financials | 10.61% |
| 5 | Consumer Discretionary | 7.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3301
Telephone and Data Systems
TDS
$4.06B
| $2.29M | ﹤0.01% |
218,797
-122,498
| -36% | -$1.52M |
2015 Q1
31 quarters
|
|
3302
National Healthcare
NHC
$3.57B
| $2.29M | ﹤0.01% |
38,480
-98,601
| -72% | -$5.98M |
2016 Q3
25 quarters
|
|
|
ZYXI
3303
DELISTED
Zynex
ZYXI
| $2.29M | ﹤0.01% |
164,333
-14,606
| -8% | -$177K |
2019 Q1
15 quarters
|
|
3304
Myers Industries
MYE
$1.17B
| $2.29M | ﹤0.01% |
102,803
+2,644
| +3% | +$54.9K |
2013 Q2
38 quarters
|
|
3305
Cartesian Therapeutics
RNAC
$205M
| $2.29M | ﹤0.01% |
67,381
-200
| -0.3% | -$8.51K |
2020 Q2
10 quarters
|
|
3306
Compass Minerals
CMP
$932M
| $2.28M | ﹤0.01% |
55,597
+6,473
| +13% | +$268K |
2015 Q4
28 quarters
|
|
3307
CALL
DraftKings
DKNG
$9.51B
| $2.28M | ﹤0.01% |
200,000
-586,900
| -75% | -$8.17M |
2021 Q2
6 quarters
|
|
3308
RXO
RXO
$4.68B
| $2.28M | ﹤0.01% |
+132,465
| New | +$2.35M |
2022 Q4
0 quarters
|
|
|
ISEE
3309
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.28M | ﹤0.01% |
+106,300
| New | +$2.27M |
2022 Q4
0 quarters
|
|
3310
Cerence
CRNC
$356M
| $2.27M | ﹤0.01% |
122,751
+210
| +0.2% | +$3.6K |
2019 Q4
12 quarters
|
|
3311
CALL
Sunrun
RUN
$1.82B
| $2.27M | ﹤0.01% |
94,600
-7,500
| -7% | -$200K |
2021 Q2
6 quarters
|
|
3312
Westamerica Bancorp
WABC
$1.34B
| $2.27M | ﹤0.01% |
38,506
-71,566
| -65% | -$4.21M |
2013 Q2
38 quarters
|
|
|
MRSN
3313
DELISTED
Mersana Therapeutics
MRSN
| $2.27M | ﹤0.01% |
15,473
+13,068
| +543% | +$2.21M |
2017 Q2
22 quarters
|
|
3314
Middlesex Water
MSEX
$996M
| $2.27M | ﹤0.01% |
28,801
-7,371
| -20% | -$640K |
2015 Q4
28 quarters
|
|
|
MODN
3315
DELISTED
MODEL N, INC.
MODN
| $2.25M | ﹤0.01% |
55,569
+24,749
| +80% | +$932K |
2016 Q4
24 quarters
|
|
|
TDCX
3316
DELISTED
TDCX Inc. American Depositary Shares, each representing one Class A ordinary share
TDCX
| $2.25M | ﹤0.01% |
181,729
| – | – |
2021 Q4
4 quarters
|
|
|
ROVR
3317
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $2.25M | ﹤0.01% |
613,185
+17,120
| +3% | +$73.4K |
2021 Q4
4 quarters
|
|
3318
U.S. Small Cap Portfolio ETF Class Shares
DFAS
$14.9B
| $2.23M | ﹤0.01% |
+43,666
| New | +$2.25M |
2022 Q4
0 quarters
|
|
3319
Fidelity Sustainable High Yield ETF
FSYD
$140M
| $2.22M | ﹤0.01% |
50,000
| – | – |
2022 Q1
3 quarters
|
|
3320
Xperi
XPER
$255M
| $2.22M | ﹤0.01% |
+257,603
| New | +$2.95M |
2022 Q4
0 quarters
|
|
3321
Mesa Laboratories
MLAB
$739M
| $2.21M | ﹤0.01% |
13,321
-176
| -1% | -$27.6K |
2017 Q4
20 quarters
|
|
|
KALV
3322
DELISTED
KalVista Pharmaceuticals
KALV
| $2.21M | ﹤0.01% |
327,003
+190,809
| +140% | +$1.02M |
2017 Q4
20 quarters
|
|
3323
Lucid Motors
LCID
$1.58B
| $2.21M | ﹤0.01% |
32,344
-6,610
| -17% | -$728K |
2020 Q3
9 quarters
|
|
3324
Vera Therapeutics
VERA
$2.07B
| $2.21M | ﹤0.01% |
113,982
+38,652
| +51% | +$700K |
2021 Q3
5 quarters
|
|
|
ARI
3325
Apollo Commercial Real Estate
ARI
$802M
| $2.2M | ﹤0.01% |
204,675
-29,980
| -13% | -$327K |
2013 Q2
38 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2022 Portfolio in Review
As of Q4 2022, JP Morgan Chase held 7,423 positions worth $759B, up 8.9% from $696B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q4 2022 filing shows 754 new, 2,939 increased, 2,285 reduced and 593 closed positions. Its largest new stake was Invesco S&P Emerging Markets Low Volatility ETF: 2,344,997 shares worth $54M. The largest sale was Invesco QQQ Trust, an estimated $1.49B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, down from 28% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q4 2022 buy was Invesco S&P Emerging Markets Low Volatility ETF: 2,344,997 shares worth $54M.
- JP Morgan Chase added most to Vanguard Tax-Exempt Bond Index Fund in Q4 2022, an estimated $2.54B increase.
- JP Morgan Chase's biggest Q4 2022 reduction was Invesco QQQ Trust, cutting an estimated $1.49B.
- JP Morgan Chase fully exited Duke Realty Corp. in Q4 2022, selling an estimated $424M.
- JP Morgan Chase's ten largest holdings make up 16% of its $759B portfolio in Q4 2022.
- JP Morgan Chase opened 754 new positions and closed 593 in Q4 2022.
- JP Morgan Chase's portfolio value rose 8.9% quarter-over-quarter to $759B.
Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.